Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186641 · ClinicalTrials.gov registry record · Phase 2
High Dose Chemotherapy and Autologous Transplant for Breast Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT00186641: Completed Phase 2 study, sponsored by Stanford University.
NCT00186641 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 203 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186641, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy
Interventions
- PROCEDURE high dose chemo and auto hematopoietic cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Est. Completion | 2008-02-08 |
| Phase | Phase 2 |
What the finished NCT00186641 record still lists
NCT00186641 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 1 intervention - of which high dose chemo and auto hematopoietic cell transplant is the first listed.
NCT00186641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186641 about?
NCT00186641 is a clinical study titled "High Dose Chemotherapy and Autologous Transplant for Breast Cancer". To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy
What is the current status of trial NCT00186641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. Estimated completion is 2008-02-08.
What interventions are being tested in trial NCT00186641?
The interventions under investigation include: high dose chemo and auto hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186641?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00186641's enrollment target sits among peer trials
203 301st of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology